Experts provide advice for patients and caregivers with relapsed/refractory multiple myeloma considering talquetamab or another bispecific, while all faculty will discuss unmet needs and future perspectives in the treatment of relapsed/refractory multiple myeloma.
Experts provide advice to patients and caregivers on managing oral and skin toxicities.
Experts discuss prophylactic measures for managing potential adverse events associated with talquetamab and other bispecifics, while all faculty will offer advice for health care providers involved in the care of patients receiving talquetamab.
Experts discuss the adverse events observed with talquetamab, including oral toxicities and skin and nail issues, and how these are managed.
Experts explore additional toxicities observed with B-cell maturation antigen–targeting bispecifics, such as infections, neurotoxicity, and hematological issues, and discuss how these are managed in practice.
Experts explain the administration of step-up and treatment doses for GPRC5D at your institution, including whether they are given in clinic or in the community, and will discuss how patients are monitored for cytokine release syndrome and immune effector cell–associated neurotoxicity syndrome during the step-up phase.
Experts address the unique challenges in managing adverse events associated with GPRC5D therapies compared to other cancer treatments, while Samantha will discuss strategies for preparing and educating patients undergoing GPRC5D therapy.
Experts give an overview of safety data from the MonumenTAL-1 study.
Experts give an overview of long-term follow-up efficacy data from the MonumenTAL-1 study.
Medical experts give an overview of relapsed/refractory multiple myeloma, focusing on diagnosis and current management strategies
September 17th 2024
September 17th 2024
